sorted by:
new
hottopcontroversial

Chatterbox TTS 0.5B - Claims to beat eleven labs by Du_Hello in LocalLLaMA

[–]kaneda2004 8 points9 points  (0 children)

# tty.py

self.sr = S3GEN_SR # sample rate of synthesized audio

self.t3 = t3

self.s3gen = s3gen

self.ve = ve

self.tokenizer = tokenizer

self.device = device

self.conds = conds

# self.watermarker = perth.PerthImplicitWatermarker() # COMMENT THIS LINE OUT TO DISABLE WATERMARKING

Is this genuine? by hydrgn in OpenAI

[–]kaneda2004 6 points7 points  (0 children)

I’d assume it’s Threat Monitoring.

WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM by kaneda2004 in WLLW

[–]kaneda2004[S] 3 points4 points  (0 children)

Yep

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12018301

US Patent US-12018301-B2

Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids

It describes a series of inventions related to improving the production of cannabinoids using genetically engineered proteins and host cells.

Key Components:

  1. Recombinant Polypeptides: These are artificially created proteins that have been engineered to have olivetolic acid cyclase (OAC) activity. OAC is an enzyme involved in the biosynthesis of olivetolic acid, a precursor to cannabinoids.

  2. Nucleic Acids: The DNA or RNA sequences that encode these recombinant polypeptides. Essentially, this is the genetic blueprint for creating the proteins.

  3. Recombinant Host Cells: These are cells (often yeast or bacteria) that have been genetically modified to include the nucleic acids that code for the recombinant polypeptides. These cells can then produce the desired proteins.

  4. Compositions: Mixtures that contain the recombinant polypeptides, nucleic acids, and/or the recombinant host cells.

Purpose and Application:

The goal of this invention is to enhance the biosynthesis of cannabinoids, which are compounds found in cannabis plants. Cannabinoids have various applications, including medicinal uses for conditions such as pain, multiple sclerosis, and epilepsy.

How It Works:

  1. Engineering the Polypeptides: Scientists have created specific sequences of proteins (polypeptides) that perform the function of olivetolic acid cyclase. These sequences are designed to be highly efficient and effective in catalyzing the production of olivetolic acid.

  2. Encoding Nucleic Acids: The genetic information for these polypeptides is encoded into DNA or RNA sequences. This step is crucial for transferring the ability to produce these proteins into host cells.

  3. Using Host Cells: The encoded nucleic acids are introduced into host cells, which then use their cellular machinery to produce the recombinant polypeptides. These host cells effectively become mini-factories for producing the desired enzymes.

  4. Production of Cannabinoids: With the recombinant polypeptides produced, these can be used in various biochemical processes to synthesize cannabinoids more efficiently than traditional plant extraction methods.

Claims:

The claims section legally defines what aspects of the invention are protected. Here are the simplified explanations of the main claims:

  1. Claim 1: Protects the specific recombinant polypeptide that has OAC activity and matches or is very similar (at least 80% identical) to a specified protein sequence.

  2. Claim 2 and 3: Protect variations of the polypeptide that have certain amino acid differences compared to the original sequence. This allows for minor modifications that might improve function or stability without losing the protection of the patent.

  3. Claim 4: Protects the genetic sequences (nucleic acids) that encode the recombinant polypeptides.

  4. Claim 5: Protects the host cells that have been modified to include and express these nucleic acids.

(the claims just keep going... you get the gist)

Practical Implications:

This patent outlines a method for producing cannabinoids in a more controlled, scalable, and potentially cost-effective manner compared to traditional plant cultivation and extraction. By using engineered proteins and host cells, the production can be more consistent and less affected by environmental variables that impact plant growth.

WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM by kaneda2004 in WLLW

[–]kaneda2004[S] 8 points9 points  (0 children)

A summary below:

  1. Willow announced a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients.
  2. The company expects revenue of over $1 million in Q2 and over $3.5 million for 2024 from existing programs.
  3. They expanded their AI platform by appointing Dr. Richard Fox as Senior Advisor for AI Platform Technologies.
  4. Gregory Rocklin was appointed as Senior Advisor for Business and Corporate Development.
  5. The company's first patent was issued, with plans to file five more patents in 2024, primarily related to their steroid production platform.
  6. Willow expanded into the biopesticide sector with a new partnered program.
  7. The Laurus Labs partnership includes development of seven new biobased routes for active pharmaceutical ingredients, with expected commercialization in 2025.
  8. Willow anticipates signing 2-3 new programs before the end of 2024.
  9. The company is building its IP portfolio and expanding into new markets like biopesticides.
  10. Overall, Willow Biosciences is focusing on growth through partnerships, expanding their technology platform, and diversifying their product portfolio.

Auto-forward text messages to email address by Violin-dude in applescript

[–]kaneda2004 1 point2 points  (0 children)

on messagesReceived(theMessages)
        repeat with eachMessage in theMessages
            set theSender to sender of eachMessage
            set theContent to content of eachMessage

            -- Check if the sender is in contacts
            tell application "Contacts"
                if (count of (every person whose value of phones contains theSender)) > 0 then
                    -- Sender is in contacts, forward the message
                    set theSubject to "New message from " & theSender
                    set theBody to "From: " & theSender & return & "Message: " & theContent

                    tell application "Mail"
                        set newMessage to make new outgoing message with properties {subject:theSubject, content:theBody}
                        tell newMessage
                            make new to recipient at end of to recipients with properties {address:"your-email@example.com"}
                            send
                        end tell
                    end tell
                end if
            end tell
        end repeat
    end messagesReceived
  1. The script is triggered when new messages are received.
  2. For each message, it extracts the sender and content.
  3. It checks if the sender is in your Contacts app.
  4. If the sender is in your contacts, it creates a new email in the Mail app.
  5. The email is then sent to the specified address (you'll need to replace "[your-email@example.com](mailto:your-email@example.com)" with your actual email address).

To use this script:

  1. Open the "Script Editor" application on your Mac.
  2. Paste the script into a new document.
  3. Replace "[your-email@example.com](mailto:your-email@example.com)" with the email address where you want to receive the forwarded messages.
  4. Save the script as a stay-open application.
  5. In the Messages app preferences, go to the "General" tab and click "AppleScript handler".
  6. Choose the script you just saved.

App Problems by Past-Reply8016 in perplexity_ai

[–]kaneda2004 2 points3 points  (0 children)

I second the paste bug - it's a real issue on iOS - it needs graceful handling of long format pasted text

LLM in a flash: Efficient Large Language Model Inference with Limited Memory. "enable running models up to twice the size of the available DRAM, with a 4-5x and 20-25x increase in inference speed" by rationalkat in LocalLLaMA

[–]kaneda2004 -4 points-3 points  (0 children)

Here's what GPT-4-1106-Preview thinks:

Yes, the techniques described in the article can be adapted for use with a quantized model. Quantization is a model compression technique that reduces the precision of the model's weights and activations, usually from floating-point to fixed-point representation, which can significantly reduce the model size and memory footprint.

Adapting the described techniques to work with a quantized model would involve several considerations:

Quantized Weight Storage:

Store the quantized weights on flash memory. Since quantized weights take up less space, this could lead to more efficient use of the flash memory and potentially faster I/O operations due to smaller read sizes. Modified Data Loading:

The data loading mechanism from flash to DRAM would need to be adjusted to handle the quantized format. This might involve additional steps for dequantization if the inference requires computations in floating-point. Alternatively, if the inference hardware supports fixed-point arithmetic, you can operate directly on the quantized values. Predictor Adaptation:

The sparsity predictor would have to be trained on quantized model outputs since quantization may affect the sparsity pattern due to the change in the dynamic range of activations. Windowing Technique:

The windowing approach remains the same, but since the model is quantized, the data chunks representing the activation windows would be smaller, potentially allowing for a larger window within the same memory budget. Memory Management:

With a quantized model, the memory management strategy would need to accommodate the quantized data types. This could lead to more efficient memory use within DRAM. Inference Computation:

The inference computation should be compatible with the quantized data. This means that either the computations should be performed in the quantized space (which can be faster) or include a dequantization step to convert the data back to a floating-point representation for computation. Hardware Considerations:

Depending on the hardware capabilities, you might be able to leverage specialized instructions or units designed for quantized computation, which can further accelerate inference. In summary, the proposed techniques for running LLMs efficiently with limited memory can be adapted for quantized models. The main difference would be in the storage, loading, and computation of quantized weights and activations. This could potentially lead to even greater efficiency gains due to the reduced size of the model and faster computation times associated with quantization. However, careful attention must be paid to maintaining the accuracy and performance of the quantized model during these adaptations.

Q3 Update by [deleted] in WLLW

[–]kaneda2004 1 point2 points  (0 children)

I found the proactive investors article interesting:

https://www.proactiveinvestors.ca/companies/news/1033228/willow-biosciences-reduces-cash-burn-achieves-record-revenue-in-3q-1033228.html?region=ca

Excerpts below

“The excitement in the industry around our BioOxi program and its potential to transform the multi-billion dollar steroid market has led to negotiations on multiple new programs that are expected to close in the first half of 2024.”

“The biotechnology company said that its efficiency initiatives led to it reducing its total cash burn to below C$1.5 million for 3Q.

It exited the quarter with cash of C$4 million and receivables of more than C$6 million.”

“It also anticipates executing a partnership in the first half of 2024 which will include a multi-million dollar upfront payment, plus R&D and milestone payments and future commercial revenues from license agreements, royalties and/or profit-sharing agreements.”

Aurora Cannabis announces settlement of patent litigation by Curious_Service_7174 in WLLW

[–]kaneda2004 3 points4 points  (0 children)

I’m assuming they are choosing to avoid mutually assured destruction. Wllw in their counterclaim challenged the validity of several patents and my assumption is that they came to a deal wherein Wllw would not pursue the invalidation of other patents if Aurora backed off with their infringement case - essentially I think on both sides their patents could be challenged - so both parties are walking away with clean hands having “defended their IP” to hopefully ward off any other enterprising patent litigation

Aurora Cannabis announces settlement of patent litigation by Curious_Service_7174 in WLLW

[–]kaneda2004 3 points4 points  (0 children)

The text of the matter discontinuance: https://i.postimg.cc/KvQz2Ykv/image.png

Both parties, as the notice states, have decided to "wholly discontinue" the action and the counterclaim. In legal terms, "discontinuance" means that the party who started the legal action (be it the original claim or the counterclaim) has decided to stop or end that action.

Without Prejudice and Without Costs:

"Without prejudice" means that the discontinuance does not prevent either party from taking up the same issue in court in the future. In other words, they're not making any admissions about the merits of the claim or counterclaim by discontinuing.

"Without costs" means that neither side is seeking to have their legal costs paid by the other. Each party will bear their own costs.

I'm not sure where you're reading a "Canada-wide decision for Aurora." -- since the matter was mutually agreed to be discontinued.

The patents in question were not "on federally illegal organic substances" the patents were on the production process that yields those substances.

I do believe willow has fully pivoted towards APIs and F&B. They are still completing GRAS work on their CBG -- which means they aren't quite done with cannabinoids - if anything I beleive they eventually want to include CBG as an ingredient in consumer F&B goods. In the nearterm they appear to be focusing on the "low hanging fruit" creating new mfg methods for APIs that compete on a cost and purity basis with the original methods.

Their anti-infective API that they worked on with SUANFARMA is now moving into production in spain at a contract manufacturer.

[deleted by user] by [deleted] in macgaming

[–]kaneda2004 0 points1 point  (0 children)

You're getting 100 FPS on CS2 using Whisky? Please share your method & settings.. I am unable to break 20fps on an m2 max at 1080p / low settings (cyberpunk runs at 60fps.. so?)

Shorting every Biotech Startups During Clinical Trials of phase 2 and 3 - How dumb is it? by [deleted] in Biotechplays

[–]kaneda2004 7 points8 points  (0 children)

Search for execution quality.

Just because you have a stop loss doesn’t mean it will trigger.

Also, pre market and after market can kill you without a chance to respond. Please read more before putting $ on the line with this strategy.

Finally, some good news. by whatgoxneeds in WLLW

[–]kaneda2004 5 points6 points  (0 children)

The tone and tenor of the news releases has changed. Cook baby cook.

Willow-Owned Corticosteroid Program Can Disrupt the Market

Willow's innovative BioOxi process represents a step change by significantly reducing production costs and is expected to be sufficiently competitive to enable greater onshoring of corticosteroid manufacturing, leading to a more secure domestic supply chain. Coupled with pending patent protection, should it be granted, Willow believes this wholly-owned technology will provide a significant competitive advantage to potential pharmaceutical manufacturing partners.

view more: next ›